CVS HEALTH CORP will restore coverage for ELI LILLY & CO weight-loss drug Zepbound and add its new obesity pill, Foundayo. The move reverses a July 1 decision to drop Zepbound in favor of NOVO NORDISK A/S-B rival drug Wegovy. It grants Lilly access to 90 million patients in the United States, potentially driving Foundayo sales in the second half of the year.

Pricing Competition Drives Formulary Shifts